#### Starting a New Program

What components does a program need to start successfully?

## Starting a new Transplant Program Essential components

Staff

**Protocols and Procedures** 

Access to advice

General guidance

#### Minimum Requirements

• What is the minimum configuration for a center to produce quality outcomes?

#### **Essential components**

- •Testing for infections cultures, CMV assay, fungal testing
- supply of necessary medications antiinfectives, immunosuppressives
- Laboratory testing to monitor drug levels
- •Transfusions—reliable and safe
- social support for patient and family adapt to budget & literacy.

#### **Basic Competence and Needs**

Experience in support and management of AML, SAA neutropenia, mucositis, infections, GI upset pulmonary complications, transfusions

Local or regional need sufficient patients with AML; DLBCL, other NHL SAA, thalassemia Myeloma, other

#### **Essential components**

- Imaging; which radiology testing is available
- Cell processing: Freezing/thawing; RBC, plasma removal; ID and quality measures
  ICU: close monitoring, cardiac and pulmonary support

 Of the essential components, which represent challenges beyond a program that already is capable of supporting patients through AML induction or prolonged SAA?

#### Minimum Essentials

• What resources or roles must be available at the center to ensure program vitality?

### Staffing needs

MDs

more than one (for vacation, travel to meetings)

training and direct experience at a BMT center

Nurses

training and experience with neutropenia, transfusions; many medications. N per patient

Pharmacists (or MD) to help drug dosing, drug interactions, availability and cost

Protocols & Procedures Patient Eligibility disease, organ function, comorbidity

Conditioning—defined and pre-planned, not patient specific.

Supportive care

Infection prevention, screening & therapy; transfusions,

nutrition—safe, sufficient, when parenteral GVHD prevention, diagnosis and therapy

#### Supportive Care

- How long does the patient require support close to the transplant center?
- How should we ensure adequate follow-up in the patient's local area?

- What about patients who are remote?

 How can the center develop local/regional networks to support referrals and post-HCT care?

#### Access to Advice

# Partner with experienced center; regional and international

Ongoing communication for protocol review, consultation

Periodic visits to other centers

Email, skype, phone don't do it alone

#### **General Guidance**

Start slow Good risk patients; need to build on success & build reputation

If patient demand justifies (sufficient NHL, myeloma) Begin with autologous HCT Build procedures, protocols, staff confidence

Move to allogeneic HCT slowly Good risk patients Suitable performance status and age Sibling donor HCT first Then only allele-matched unrelated donors Selected testing of haplo or UCB new approaches